HPLC-UV Rat blood 100 µ L Deproteinization Gradient NR Partial [11] LLE: liquid-liquid extraction; SPE: solid-phase extraction; NR: not reported. [12] fu,mic,KET 0.97 Unbound fraction of KET in HLM [12] IC50 (μM) 0.0549 Figure 7B S (μM) 5 Figure 7B Km (μM) 51.6 Figure 7A Ki ( Based on the FDA guidance [14] , the magnitude of in vivo clinical DDIs between DUT and KET was predicted using the basic (simple static) model as below, assuming that DUT is eliminated exclusively by hepatic CYP3A-mediated metabolism and KET acts as a competitive inhibitor for DUT metabolism [12] .
R = 1 + Imax,u/Ki
where the R is the predicted ratio of the AUC of DUT in the presence and absence of KET, the Imax,u is the maximum unbound plasma concentration of KET, and the Ki is the unbound inhibition constant of KET determined in vitro. Since IC50 only was determined in this study, it was converted to Ki using the following equation for competitive inhibition [15] .
Ki = IC50/(S/Km + 1)
where the S is the fixed concentration of DUT, and the Km is the Michaelis-Menten constant. The parameters relevant to the estimation of R value are listed in Table S2 . Based on the FDA guidance [16] and R value, it is plausible that KET acts as an in vivo moderate inhibitor for DUT metabolism in clinical setting, which warrants further in vivo clinical investigation on the potential of pharmacokinetic interactions of DUT with KET and other chronic CYP3A inhibitors (e.g., ritonavir).
